medigraphic.com
Instituto Nacional de Neurología y Neurocirugía

2023, Number 3

<< Back Next >>

Arch Neurocien 2023; 28 (3)

Características clínicas de los pacientes diagnosticados con síndrome de Guillain Barré en tres instituciones especializadas de la ciudad de Medellín, 2015-2020

Barón CAF, García FLF, Manco SE, Cataño S, Arteaga A, Vallejo D, Zapata JF, Castro-Álvarez JF

Language: Spanish
References: 33
Page: 15-20
PDF size: 210.23 Kb.


ABSTRACT

No abstract.


REFERENCES

  1. Doets AY, Verboon C, van den Berg B, Harbo T, Cornblath DR,Willison HJ, et al. Regional variation of Guillain-Barré syndrome.Brain. 2018;141(10):2866-77. doi: 10.1093/brain/awy232

  2. Leonhard SE, Mandarakas MR, Gondim FAA, Bateman K,Ferreira MLB, Cornblath DR, et al. Diagnosis and managementof Guillain–Barré syndrome in ten steps. Nat Rev Neurol.2019;15(11):671-83. doi: 10.1038/s41582-019-0250-9

  3. Mahecha MP, Ojeda E, Vega DA, Sarmiento-Monroy JC,Anaya JM. Guillain-Barré syndrome in Colombia: where do westand now? Immunol Res. 2017;65(1):72-81. doi: 10.1007/s12026-016-8816-8

  4. Laman JD, Huizinga R, Boons GJ, Jacobs BC. Guillain-Barrésyndrome: expanding the concept of molecular mimicry. TrendsImmunol. 2022;43(4):296-308. doi: 10.1016/j.it.2022.02.003

  5. Jacobs BC, Rothbarth PH, van der Meché FG, Herbrink P, SchmitzPI, de Klerk MA, et al. The spectrum of antecedent infections inGuillain-Barré syndrome. Neurology. 1998;51(4):1110-5. doi:10.1212/WNL.51.4.1110

  6. Wanschitz J, Maier H, Lassmann H, Budka H, Berger T. Distincttime pattern of complement activation and cytotoxic T cellresponse in Guillain-Barré syndrome. Brain. 2003;126(9):2034-42. doi: 10.1093/brain/awg207

  7. Yuki N, Yamada M, Koga M, Odaka M, Susuki K, TagawaY, et al. Animal model of axonal Guillain-Barré syndromeinduced by sensitization with GM1 ganglioside. Ann Neurol.2001;49(6):712-20. doi: 10.1002/ana.1012

  8. González-Suárez I, Sanz-Gallego I, Rodríguez de Rivera FJ,Arpa J. Guillain-Barré syndrome: natural history and prognosticfactors: a retrospective review of 106 cases. BMC Neurol.2013;13(1):95. doi: 10.1186/1471-2377-13-95

  9. Fokke C, Van Den Berg B, Drenthen J, Walgaard C, Van DoornPA, Jacobs BC. Diagnosis of Guillain-Barré syndrome andvalidation of Brighton criteria. Brain. 2014;137(1):33-43. doi:

  10. 10.1093/brain/awt28510. van der Meché FGA, Schmitz PIM. A randomized trial comparingintravenous immune globulin and plasma exchange in Guillain–Barré syndrome. N Engl J Med. 1992;326(17):1123-9. doi:10.1056/NEJM199204233261705

  11. Shahrizaila N, Lehmann HC, Kuwabara S. Guillain-Barrésyndrome. Lancet. 2021;397(10280):1214-28. doi: 10.1016/S0140-6736(21)00517-1

  12. Parra B, Lizarazo J, Jiménez-Arango JA, Zea-Vera AF, González-Manrique G, Vargas J, et al. Guillain–Barré syndromeassociated with Zika virus infection in Colombia. N Engl J Med.2016;375(16):1513-23. doi: 10.1056/nejmoa1605564

  13. Salinas JL, Walteros DM, Styczynski A, Garzón F, Quijada H,Bravo E, et al. Zika virus disease-associated Guillain-Barrésyndrome—Barranquilla, Colombia 2015–2016. J Neurol Sci.2017;381:272-7. doi: 10.1016/j.jns.2017.09.001

  14. Méndez N, Oviedo-Pastrana M, Mattar S, Caicedo-Castro I,Arrieta G. Zika virus disease, microcephaly and Guillain-Barrésyndrome in Colombia: Epidemiological situation during 21months of the Zika virus outbreak, 2015-2017. Arch PublicHeal. 2017;75(1):1-11. doi: 10.1186/s13690-017-0233-5

  15. Anaya JM, Rodríguez Y, Monsalve DM, Vega D, Ojeda E,González-Bravo D, et al. A comprehensive analysis andimmunobiology of autoimmune neurological syndromes duringthe Zika virus outbreak in Cúcuta, Colombia. J Autoimmun.2017;77:123-38. doi: 10.1016/j.jaut.2016.12.007

  16. Sipilä JOT, Soilu-Hänninen M, Ruuskanen JO, Rautava P, KytöV. Epidemiology of Guillain-Barré syndrome in Finland 2004-2014. J Peripher Nerv Syst. 2017;22(4):440-5. doi: 10.1111/jns.12239

  17. Papri N, Islam Z, Leonhard SE, Mohammad QD, Endtz HP,Jacobs BC. Guillain–Barré syndrome in low-income and middleincomecountries: challenges and prospects. Nat Rev Neurol.2021;17(5):285-96. doi: 10.1038/s41582-021-00467-y

  18. Isaza S, Pérez A UC. Descripción de los casos de síndrome deGuillain Barré en el Hospital San Vicente de Paúl entre los años2001 y 2005. Acta Neurol Colomb. 2009;25(3):123-9.

  19. González P, García X, Guerra A, Arango JC, Delgado H,Uribe CS, et al. Experience with Guillain-Barré syndrome in aneurological Intensive Care Unit. Neurologia. 2016;31(6):389-94. doi: 10.1016/j.nrl.2014.09.004

  20. López-Hernández JC, Galnares-Olalde JA, Gutiérrez A, EstradaSA, García-Grimshaw M, Vargas-Cañas ES. Síndrome deGuillain-Barré en México : características clínicas y validaciónde los criterios de Brighton. Rev Neurol. 2022;74(8):258-64.doi: 10.33588/rn.7408.2021437

  21. Gómez Á, Díaz A, Carrión‐Penagos J, Reyes J, Reyes S. Clinicaland electrophysiological characteristics of Guillain‐Barrésyndrome in Colombia. J Peripher Nerv Syst. 2019;24(3):268-71. doi: 10.1111/jns.12340

  22. Al-Hakem H, Sindrup SH, Andersen H, de la Cour CD, LassenLL, van den Berg B, et al. Guillain–Barré syndrome in Denmark:a population-based study on epidemiology, diagnosis andclinical severity. J Neurol. 2019;266(2):440-9. doi: 10.1007/s00415-018-9151-x

  23. Forsberg A, Press R, Holmqvist LW. Residual disability 10 yearsafter falling ill in Guillain–Barré syndrome: A prospective followupstudy. J Neurol Sci. 2012;317(1–2):74-9. doi: 10.1016/j.jns.2012.02.026

  24. Pollak TA, Lennox BR, Müller S, Benros ME, Prüss H, Tebartzvan Elst L, et al. Autoimmune psychosis: an internationalconsensus on an approach to the diagnosis and managementof psychosis of suspected autoimmune origin. Lancet Psychiatry.2020;7(1):93-108. doi: 10.1016/S2215-0366(19)30290-1

  25. Benedetti MD, Pugliatti M, D'Alessandro R, Beghi E,Chiò A, Logroscino G, et al. A multicentric prospectiveincidence study of Guillain-Barré syndrome in Italy. TheITANG Study. Neuroepidemiology. 2015;45(2):90-9. doi:10.1159/000438752

  26. Kobori S, Kubo T, Otani M, Muramatsu K, Fujino Y, AdachiH, et al. Coexisting infectious diseases on admission as a riskfactor for mechanical ventilation in patients with Guillaine-Barrésyndrome. J Epidemiol. 2017;27(7):311-6. doi: 10.1016/j.je.2016.07.003

  27. Delannoy A, Rudant J, Chaignot C, Bolgert F, Mikaeloff Y,Weill A. Guillain-Barré syndrome in France: a nationwideepidemiological analysis based on hospital discharge data(2008-2013). J Peripher Nerv Syst. 2017;22(1):51-8. doi:10.1111/jns.12202

  28. Aragonès JM, Altimiras J, Alonso F, Celedón G, Alfonso S, RouraP, et al. Incidencia y características clínicas del síndrome deGuillain-Barré en la comarca de Osona (Barcelona, España)(2003-2016). Neurología. 2021;36(7):525-30. doi: 10.1016/j.nrl.2018.03.021

  29. Walgaard C, Lingsma HF, Ruts L, Van Doorn PA, Steyerberg EW,Jacobs BC. Early recognition of poor prognosis in Guillain-Barrésyndrome. Neurology. 2011;76(11):968-75. doi: 10.1212/WNL.0b013e3182104407

  30. Márquez Rosales BA, Vargas Rodríguez LJ, Guerra Guerra LI.Caracterización del síndrome de Guillain-Barré en pacientesatendidos en un hospital en Colombia entre el año 2009 y el2019. Neurol Argentina. 2022;14(4):208-14. doi: 10.1016/j.neuarg.2021.10.003

  31. Millán S, Díaz C, David Pardo DG, Castro Guzmán G. Clinicaland neurophysiological characteristics of patients with Guillain-Barré syndrome at Hospital Universitario San Ignacio, Bogotá,Colombia between 2009 and 2017. J Peripher Nerv Syst.2019;24(3):272-5. doi: 10.1111/jns.12345

  32. Lynch RM, Mantus G, Encinales L, Pacheco N, Li G, PorrasA, et al. Augmented zika and dengue neutralizing antibodiesare associated with Guillain-Barré syndrome. J Infect Dis.2019;219(1):26-30. doi: 10.1093/infdis/jiy466

  33. Charniga K, Cucunubá ZM, Walteros DM, Mercado M, PrietoF, Ospina M, et al. Descriptive analysis of surveillance datafor Zika virus disease and Zika virus-associated neurologicalcomplications in Colombia, 2015–2017. PLoS One.2021;16(6):e0252236. doi: 10.1371/journal.pone.0252236




2020     |     www.medigraphic.com